To the best of our knowledge, we did not find any reported case of acute pancreatitis related to durvalumab or anti-PD-L1 therapy.[2,3] In PACIFIC trials, irAEs (all grades) are reported in 24.2% of the patients in the durvalumab group.[1] According to a meta-analysis published in 2016, the incidence of acute pancreatitis associated with anti-PD-1 was 1.8%.[4] In a systematic review and meta-analysis,[3] Su et al underline the rarity of acute pancreatitis associated with different ICI (cytotoxic T lymphocyte antigen 4 [CTLA-4]: 0.9%–3%, PD-1: 0.5%–1.6%, CTLA-4 + PD-1: 2%–2.1%). Here, CTLA4 is linked to acute pancreatitis.